Mutagenic potential of temozolomide in bone marrow cells in vivo

Abstract excerpt

Therapy-related myeloid leukemias (t-MLs) occur in as many as 5% to 10% of patients who are otherwise cured of a primary neoplasm with aggressive multimodal regimens. Many patients with t-MLs or therapy-related myelodysplastic syndrome (t-MDS) have previously received chemotherapeutic agents that

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Brain Metastases and Treatment
• Share to Glioma Diagnosis and Treatment
• Share to Histone Deacetylase Inhibitors Research